Ho Peter Tai-Ching
Chief Development Officer at Epizyme, Inc.
- Sold, on record
- $1.4M
- Dollars the filings state
- Form 4 sales
- 7
- Latest Oct 24, 2017
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- Epizyme, Inc.Chief Development Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale Epizyme, Inc.Plan not statedDec 8, 2016 2016
Sold 200 shares at $10.89 ($2k)
Ho Peter Tai-Ching, Chief Development Officer
Sold 3.5% of holdings ($62k position)5,520 shares leftFirst sale on recordFiling
- 2 Form 4 sale Epizyme, Inc.UnusualMay 25, 2017 +168 days
Sold 15,000 shares at $16.11 ($242k)
Ho Peter Tai-Ching, Chief Development Officer
Sold 67.5% of holdings ($358k position)7,228 shares leftFiling
- 3 Form 4 sale Epizyme, Inc.UnusualJun 26, 2017 +32 days
Sold 15,000 shares at $14.87 ($223k)
Ho Peter Tai-Ching, Chief Development Officer
Sold 67.5% of holdings ($331k position)7,228 shares leftFiling
- 4 Form 4 sale Epizyme, Inc.UnusualJul 24, 2017 +28 days
Sold 15,000 shares at $13.44 ($202k)
Ho Peter Tai-Ching, Chief Development Officer
Sold 67.5% of holdings ($299k position)7,228 shares left1x usual sizeFiling
- 5 Form 4 sale Epizyme, Inc.UnusualAug 24, 2017 +31 days
Sold 15,000 shares at $15.68 ($235k)
Ho Peter Tai-Ching, Chief Development Officer
Sold 67.5% of holdings ($349k position)7,228 shares left1x usual sizeFiling
- 6 Form 4 sale Epizyme, Inc.UnusualSep 25, 2017 +32 days
Sold 15,000 shares at $16.81 ($252k)
Ho Peter Tai-Ching, Chief Development Officer
Sold 64.9% of holdings ($389k position)8,123 shares left1x usual sizeFiling
- 7 Form 4 sale Epizyme, Inc.UnusualOct 24, 2017 +29 days
Sold 15,000 shares at $16.44 ($247k)
Ho Peter Tai-Ching, Chief Development Officer
Sold 64.9% of holdings ($380k position)8,123 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (7)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Oct 24, 2017 | Oct 25, 2017 | Epizyme, Inc. | Chief Development Officer | Form 4 sale | 15,000 | $247k | 64.9% | Unusual | SEC |
| Sep 25, 2017 | Sep 26, 2017 | Epizyme, Inc. | Chief Development Officer | Form 4 sale | 15,000 | $252k | 64.9% | Unusual | SEC |
| Aug 24, 2017 | Aug 28, 2017 | Epizyme, Inc. | Chief Development Officer | Form 4 sale | 15,000 | $235k | 67.5% | Unusual | SEC |
| Jul 24, 2017 | Jul 26, 2017 | Epizyme, Inc. | Chief Development Officer | Form 4 sale | 15,000 | $202k | 67.5% | Unusual | SEC |
| Jun 26, 2017 | Jun 27, 2017 | Epizyme, Inc. | Chief Development Officer | Form 4 sale | 15,000 | $223k | 67.5% | Unusual | SEC |
| May 25, 2017 | May 26, 2017 | Epizyme, Inc. | Chief Development Officer | Form 4 sale | 15,000 | $242k | 67.5% | Unusual | SEC |
| Dec 8, 2016 | Dec 12, 2016 | Epizyme, Inc. | Chief Development Officer | Form 4 sale | 200 | $2k | 3.5% | Plan not stated | SEC |